Latest research on Mometasone Furoate

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. he antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Mometasone Furoate dosage

A diagnosis of lichenoid drug eruption secondary to Tenofovir was made and the patient was started on oral corticosteroids at a dose of 30 mg/day of Prednisolone along with topical corticosteroids (Mometasone Furoate 0.1% cream twice daily), emollients and oral anti-histamines. [source, 2015]
QMF149 is a once-daily fixed-dose combination of the LABA indacaterol maleate and the ICS Mometasone Furoate (MF), which have both demonstrated 24 h duration of action as monotherapies. [source, 2015]
After a 4-week washout period of both oral and intranasal steroids (week 0), 55 patients received systemic steroid (oral Prednisone) at 25 mg in a single daily dose for 2 weeks, followed by maintenance using a long-term intranasal steroid (e.g., Mometasone Furoate aqueous nasal spray at 200 μg/day). [source, 2014]
Daily rescue medication use for AR/C was transformed to a DMS by applying score/dose units for DESLORATADINE, Olopatadine ophthalmic solution, Mometasone Furoate nasal spray, and Prednisone tablets (Table 1) [13]. [source, 2014]
The patients were randomly divided into two groups depending on the topical Nasal steroid treatment: Group A with 200 micrograms dose of Mometasone Furoate (MF) and group B with 110 micrograms dose of Fluticasone furoate (FF), both administered in the morning during 4 weeks. [source, 2013]
Conventional FDA-approved solutions available by metered-dose, low-volume topical sprays include Fluticasone proprionate, Mometasone Furoate, ciclesonide, Budesonide, Flunisolide, Fluticasone furoate, Beclomethasone dipropionate monohydrate, and Triamcinolone Acetonide. [source, 2013]
The gradient RP-HPLC method developed for eberconazole nitrate and Mometasone Furoate related substances in pharmaceutical dosage forms is found precise, accurate, linear, robust, rugged and specific. [source, 2013]
A gradient RP-HPLC method was successfully developed for the simultaneous determination of phenoxyethanol, methylparaben, propylparaben, Mometasone Furoate, and Tazarotene in topical pharmaceutical dosage form. [source, 2013]
Moreover, it may be applied for the individual and simultaneous determination of phenoxyethanol, methylparaben, propylparaben, Mometasone Furoate, and Tazarotene in the study of content uniformity, tube homogeneity, and invitro release test profiling of Mometasone Furoate and Tazarotene topical pharmaceutical dosage forms, where the sample load is higher and the high throughput is essential for the faster delivery of results. [source, 2013]
Mometasone Furoate (MF) in a dry-powder inhaler administered at a total daily dose of 800 μg for 12 months demonstrated significant improvements compared with placebo in lung function, time-to-first exacerbation, number of exacerbations, symptoms, and health status. [source, 2012]